Treatment of HCV Genotype-1a Infection with Sofosbuvir/ Daclatasvir in a Child Suffering from Thalassemia-Major | [RADS Journal of Pharmacy & Pharmaceutical Sciences • 2020]

Author(s):

1. Hafiz Javed Mansoor: Mughal Medical Centre, Mughal Eye Hospital, JoharTown Lahore, Pakistan; Faculty of Pharmacy, The University of Lahore-Lahore Pakistan; Department of Chemistry and Chemical Engineering, Syed Babar Ali School of Science and Engineering, Lahore University of Management Science, Lahore, Pakistan

2. Muhammad Salman Walayt: Mughal Medical Centre, Mughal Eye Hospital, JoharTown Lahore, Pakistan

3. Hammad Ahmed: Faculty of Pharmacy, The University of Lahore-Lahore Pakistan

4. Mahtab Ahmad Khan: Faculty of Pharmacy, The University of Central Punjab, Lahore Pakistan

5. Muhammad Saeed: Department of Chemistry and Chemical Engineering, Syed Babar Ali School of Science and Engineering, Lahore University of Management Science, Lahore, Pakistan

Abstract:

Background: Beta thalassemia is the most common genetically transmitted disorder throughout the world. The life of a thalassemia patient depends on continuous blood transfusions, that can lead to various blood-borne viral infections mainly human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections. Nevertheless, HCV infection is the most prevalent among blood transfusion-related blood-borne infections. Co-occurrence of thalassemia major with hepatic fibrosis,severe anemia, and iron over-load complicates HCV treatment. Additionally, treatment of HCV infection generally results in the manifestation of several drug-associated side effects, and the burden of continuous blood transfusions makes the condition worse. Aim: Efficacy and safety of Sofosbuvir/ Daclatasvir in a HCV infected child suffering from thalassemia major. Method: The patient was treated with direct-acting antiviral drugs including Sofosbuvir/ Daclatasvir for twenty weeks. The complete blood count (CBC) and Liver function test (LFT) data were obtained during the whole treatment. The efficacy and safety of treatment was evaluated by CBC and LFT values. The whole data was evaluated by Microsoft excel 2013. Result: No significant side effect was observed during the whole treatment. The hemoglobin (Hb) level remained normal and did not require additional blood transfusion. The end of therapy response (ETR) was achieved after twenty weeks of treatment. Conclusion: Sofosbuvir/ Daclatasvir were found effective in the thalassemia patient. There was no need for dose adjustment. The sustained viral response (SVR24) was achieved.

Page(s): 168-172

DOI: DOI not available

Published: Journal: RADS Journal of Pharmacy & Pharmaceutical Sciences, Volume: 8, Issue: 3, Year: 2020

Keywords:

ßthalassemia , SofosbuvirDaclatasvir , Hepatitis C virus infection , HCV genotype1a

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views